These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 19457245)

  • 1. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.
    Bathe OF; Ernst S; Sutherland FR; Dixon E; Butts C; Bigam D; Holland D; Porter GA; Koppel J; Dowden S
    BMC Cancer; 2009 May; 9():156. PubMed ID: 19457245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
    Seium Y; Stupp R; Ruhstaller T; Gervaz P; Mentha G; Philippe M; Allal A; Trembleau C; Bauer J; Morant R; Roth AD
    Ann Oncol; 2005 May; 16(5):762-6. PubMed ID: 15817597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
    Bathe OF; Dowden S; Sutherland F; Dixon E; Butts C; Bigam D; Walley B; Ruether D; Ernst S
    BMC Cancer; 2004 Jul; 4():32. PubMed ID: 15245580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
    Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
    Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
    Ychou M; Viret F; Kramar A; Desseigne F; Mitry E; Guimbaud R; Delpero JR; Rivoire M; Quénet F; Portier G; Nordlinger B
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):195-201. PubMed ID: 17901955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
    Skof E; Rebersek M; Hlebanja Z; Ocvirk J
    BMC Cancer; 2009 Apr; 9():120. PubMed ID: 19386096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.
    Pozzo C; Basso M; Cassano A; Quirino M; Schinzari G; Trigila N; Vellone M; Giuliante F; Nuzzo G; Barone C
    Ann Oncol; 2004 Jun; 15(6):933-9. PubMed ID: 15151951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
    Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
    Berardi G; De Man M; Laurent S; Smeets P; Tomassini F; Ariotti R; Hoorens A; van Dorpe J; Varin O; Geboes K; Troisi RI
    Eur J Surg Oncol; 2018 Jul; 44(7):1069-1077. PubMed ID: 29615295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
    Bendell JC; Zakari A; Peyton JD; Boccia R; Moskowitz M; Gian V; Lipman A; Waterhouse D; LoCicero R; Earwood C; Lane CM; Meluch A
    Oncologist; 2016 Mar; 21(3):279-80. PubMed ID: 26911408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
    Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
    Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
    Miller CL; Taylor MS; Qadan M; Deshpande V; Worthington S; Smalley R; Collura C; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Parikh AR; Berger D; Tanabe KK; Lillemoe KD; Ferrone CR
    J Gastrointest Surg; 2017 Nov; 21(11):1831-1840. PubMed ID: 28884391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
    Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
    Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
    Min BS; Kim NK; Ahn JB; Roh JK; Kim KS; Choi JS; Cha SH; Kim H
    Onkologie; 2007 Dec; 30(12):637-43. PubMed ID: 18063876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.
    Idelevich E; Greif F; Mavor E; Miller R; Kashtan H; Susmalian S; Ariche A; Brenner B; Baruch NB; Dinerman M; Shani A
    Chemotherapy; 2009; 55(2):76-82. PubMed ID: 19077422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
    Hsu HC; Chou WC; Shen WC; Wu CE; Chen JS; Liau CT; Lin YC; Yang TS
    Anticancer Res; 2013 Aug; 33(8):3317-25. PubMed ID: 23898098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
    Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
    Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.
    Moehler M; Hoffmann T; Zanke C; Hohl H; Burg H; Ehscheid P; Schwindt P; Adami B; Schroeder M; Klein O; Baldus M; Galle PR; Heike M
    Anticancer Drugs; 2003 Jan; 14(1):79-85. PubMed ID: 12544262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.
    Sahajpal A; Vollmer CM; Dixon E; Chan EK; Wei A; Cattral MS; Taylor BR; Grant DR; Greig PD; Gallinger S
    J Surg Oncol; 2007 Jan; 95(1):22-7. PubMed ID: 17066435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
    Adam R; Pascal G; Castaing D; Azoulay D; Delvart V; Paule B; Levi F; Bismuth H
    Ann Surg; 2004 Dec; 240(6):1052-61; discussion 1061-4. PubMed ID: 15570210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.